Technical Trade Alerts on Market Movers: CABN, ISPH, GFIG, COMS, MERC, ATML
Carbon Sciences (CABN) shares slipped 6.67% Friday afternoon, closing at 14 cents. Carbon Sciences engages in developing a technology called GreenCarbon Technology to convert the greenhouse gas, carbon dioxide (CO2), into a useful form that will not contr
(EMAILWIRE.COM, September 30, 2008 ) DALLAS, Texas – BeaconEqutiy announces the publication of Trade Alerts for companies making moves in the market. Today's Trade Alerts include: Carbon Sciences Inc. (OTCBB: CABN), Inspire Pharmaceuticals Inc. (Nasdaq: ISPH), GFI Group Inc. (Nasdaq: GFIG), 3Com Corp. (Nasdaq: COMS), Mercer International Inc. (Nasdaq: MERC) and Atmel Corp. (Nasdaq: ATML).
In the Trade Alert, the company highlights Carbon Sciences share activity and upcoming news:
“Carbon Sciences (CABN) shares slipped 6.67% Friday afternoon, closing at 14 cents. Carbon Sciences engages in developing a technology called GreenCarbon Technology to convert the greenhouse gas, carbon dioxide (CO2), into a useful form that will not contribute to global warming. The company today announced the completion of its initial technology development phase … Carbon Sciences said it is currently in discussions with potential partners regarding licensing and further co-development efforts of its CO2-to-Carbonate technology.”
The company also said its conversion technology will be used to produce various fuels:
“The company also recently announced it is developing a breakthrough technology to transform CO2 into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.”
The Trade Alert author also featured Inspire Pharmaceuticals for its news on Prolacria, a treatment for dry eye disease:
“Inspire Pharmaceuticals (ISPH) shares climbed 7.32% in Friday’s trading, settling at $3.52. Inspire is a biopharmaceutical company focusing on discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs … The company recently submitted a clinical protocol and request for special protocol assessment to the FDA for a pivotal phase III environmental trial with Prolacria for the treatment of dry eye disease.”
According to the article, dry eye disease is a common affliction, and Inspire is working to address medical needs:
“Prolacria is an internally developed P2Y2 receptor agonist being developed by Inspire as an eye drop that stimulates release of the three natural tear components involved in tear secretion - mucin, lipids and fluid. Inspire estimates, based on an extrapolation from U.S. data, that dry eye disease affects more than 30 million people in the eight major international prescription pharmaceutical markets, of which more than 9 million are in North America.”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEB SITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
The report is a service of BlueWave Advisors, LLC, a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed within each individual profile in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. BlueWave Advisors, LLC, and/or its affiliated will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. BeaconEquity.com is a Web site wholly-owned by BlueWave Advisors, LLC. Principals of BlueWave Advisors, LLC have purchased three hundred thousand shares of restricted stock from CABN at 15 cents per share; additionally, BlueWave Advisors, LLC and its affiliates have been compensated fifteen thousand dollars a month directly from Carbon Sciences Inc. as a marketing budget to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
In the Trade Alert, the company highlights Carbon Sciences share activity and upcoming news:
“Carbon Sciences (CABN) shares slipped 6.67% Friday afternoon, closing at 14 cents. Carbon Sciences engages in developing a technology called GreenCarbon Technology to convert the greenhouse gas, carbon dioxide (CO2), into a useful form that will not contribute to global warming. The company today announced the completion of its initial technology development phase … Carbon Sciences said it is currently in discussions with potential partners regarding licensing and further co-development efforts of its CO2-to-Carbonate technology.”
The company also said its conversion technology will be used to produce various fuels:
“The company also recently announced it is developing a breakthrough technology to transform CO2 into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.”
The Trade Alert author also featured Inspire Pharmaceuticals for its news on Prolacria, a treatment for dry eye disease:
“Inspire Pharmaceuticals (ISPH) shares climbed 7.32% in Friday’s trading, settling at $3.52. Inspire is a biopharmaceutical company focusing on discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs … The company recently submitted a clinical protocol and request for special protocol assessment to the FDA for a pivotal phase III environmental trial with Prolacria for the treatment of dry eye disease.”
According to the article, dry eye disease is a common affliction, and Inspire is working to address medical needs:
“Prolacria is an internally developed P2Y2 receptor agonist being developed by Inspire as an eye drop that stimulates release of the three natural tear components involved in tear secretion - mucin, lipids and fluid. Inspire estimates, based on an extrapolation from U.S. data, that dry eye disease affects more than 30 million people in the eight major international prescription pharmaceutical markets, of which more than 9 million are in North America.”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEB SITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
The report is a service of BlueWave Advisors, LLC, a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed within each individual profile in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. BlueWave Advisors, LLC, and/or its affiliated will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. BeaconEquity.com is a Web site wholly-owned by BlueWave Advisors, LLC. Principals of BlueWave Advisors, LLC have purchased three hundred thousand shares of restricted stock from CABN at 15 cents per share; additionally, BlueWave Advisors, LLC and its affiliates have been compensated fifteen thousand dollars a month directly from Carbon Sciences Inc. as a marketing budget to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Contact Information:
Beacon Equity Research
Jef Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity Research
Jef Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |